AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$WST

Favorite Annette F sold $2.8M of WST

Favorite Annette F (Sr. VP & Chief HR Officer) sold 8,135 shares of WEST PHARMACEUTICAL SERVICES INC (WST) at $340.81 ($2.77M total) across 3 trades on 2026-09-08.

Original reporting
SEC EDGAR · Favorite Annette F
Published Sep 10, 2026, 9:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$WST
Neutral
medium confidence
Mentioned
$WST
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WSTNeutralLow
01

Why it matters

The disclosure provides fresh data on insider holdings, useful for short‑term monitoring but unlikely to drive significant price movement.

02

Market read

Primary insider filing; modest size limits market impact.

03

What to watch

Potential upcoming compensation package or tax planning could explain the sale without implying negative outlook.

Relevance 6/10Novelty 6/10Timing: post‑market 2026-09-08

Background

West Pharmaceutical Services (WST) filed a Form 4 reporting an insider sale by a senior executive.

Company-level read

Ticker impact

$WSTNeutralMedium confidence
Context

Senior VP & Chief HR Officer sold 8,135 shares for $2.77M on 2026-09-08, reducing her stake to 16,845 shares.

Expected impact

Potential short-term pressure on the stock, likely limited to a few basis points.

Evidence & confidence

Form 4 is a primary disclosure; however, the transaction amount is relatively small for a mid‑cap, so market reaction is expected to be muted.

Market effects

Sector

Minimal impact on the pharmaceutical services sector; insider sales are routine.

Regional

No discernible regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be unrelated to company fundamentals and merely personal liquidity needs.

Key entities

  • Company
    West Pharmaceutical Services Inc.

    US‑listed pharmaceutical services provider (ticker WST).

  • Insider
    Favorite Annette F.

    Senior VP & Chief HR Officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

WST insider trading history →

Related articles

OCT 31
$WSTHighAI 8/10

What West Pharmaceutical Services (WST) Said on Its Q3 Earnings Call

West Pharmaceutical Services reported Q3 revenue of $874M, up 8.7%, with adjusted EPS increasing 36% to $2.66. Strong demand for biologics and GLP-1 therapies drove growth, particularly in proprietary products. The company raised its 2026 outlook, forecasting revenue of $3.41B-$3.42B and adjusted EPS of $9.38-$9.48. West is also expanding HVP capacity and maintaining dividend and share repurchase programs.

finance.yahoo.com2 min
OCT 29
$WSTMed

West Pharmaceutical Services, Inc. Q3 2026 Earnings Call Summary

West Pharmaceutical Services reported Q3 2026 earnings, highlighting 16.6% growth in proprietary products, driven by HVP components and GLP-1 treatments. Gross margins expanded by 310 basis points due to a shift toward high-value products. The company raised full-year organic growth guidance to 11.3%-11.6% and announced an 18% dividend increase. Management discussed strategic shifts, including divestitures and capital investments in HVP capacity.

finance.yahoo.com6 min
OCT 29
$WSTMedAI 8/10

West Pharmaceutical Services Inc (WST) (Q3 2026) Earnings Call Highlights: Record Margins

West Pharmaceutical Services reported Q3 2026 earnings with record margins, but faced revenue declines in the West Vantage segment and a planned divestiture headwind. Free cash flow decreased 5% year-over-year. CEO Michel Lagarde emphasized strong organic growth prospects and high M&A criteria. GLP-1 revenue growth is expected to decelerate due to tough comparisons. The company anticipates continued margin expansion and plans to invest in high-return HVP areas.

finance.yahoo.com3 min